The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Development and validation of an assay to quantify plasma cell-free human papillomavirus DNA for 13 high-risk types that cause 98% of HPV-positive cancers.
 
Michael Wotman
No Relationships to Disclose
 
Weihong Xiao
No Relationships to Disclose
 
Robyn Du
No Relationships to Disclose
 
Bo Jiang
No Relationships to Disclose
 
Suyu Liu
No Relationships to Disclose
 
Maura L. Gillison
Consulting or Advisory Role - Abbvie; Adaptimmune; Aptitude Health; Axiom Biotechnologies; Bayer; Bicara Therapeutics; Bicara Therapeutics; BioNTech; BioNTech; BioNTech SE; Bristol-Myers Squibb; Bristol-Myers Squibb/Roche; Caladrius Biosciences; Coherus Biosciences; Coherus Biosciences; Debiopharm Group; Eisai; EMD Serono; EMD Serono; END Merck; Exelixis; Gilead Sciences; Guidepoint Global; Ipsen; Istari; ITeos Therapeutics; Journal of Clinical Oncology; Kura Oncology; LLX Solutions; LLX Solutions; Merck; Merus; Mirati Therapeutics; Nektar; OncLive; Seagen; Sensei Biotherapeutics; Shattuck Labs; Surface Oncology
Research Funding - Agenus (Inst); Bristol-Myers Squibb (Inst); Cullinan Oncology (Inst); Genentech (Inst); Genocea Biosciences (Inst); Kura Oncology (Inst); Seagen (Inst)